Veklury Still Keeping Gilead Above Water Amid Pandemic, Patent Expiries
HIV, Hepatitis Continue To See Sales Declines
Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.
You may also be interested in...
While much earlier in its development, the drug may be able to rival Gilead’s Trodelvy, which also targets TROP2 and showed similar response rates.
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.
The CDC and FDA recommended a pause on dosing of J&J's one-shot vaccine. Pfizer/BioNTech's vaccine showed signs of lower efficacy against the B.1.351 variant, but a prominent expert called the data "misleading." Gilead halted its Phase III study of Veklury in non-hospitalized, high-risk patients. And Rigel's Tavalisse may have a shot in the sickest COVID-19 patients despite the small size of a Phase II study.